Imperial College London

Dr. David James PINATO

Faculty of MedicineDepartment of Surgery & Cancer

Clinical Senior Lecturer in Medical Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2799david.pinato Website

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Collaborators

Prof Mario Pirisi, Università del Piemonte Orientale "A. Avogadro", 2008

Guest Lectures

Treatment Landscape of hepatocellular carcinoma, Roche ACT academy, Faculty, Dublin (Ireland), 2019

Cancer Immunotherapy in Early or Intermediate HCC, ESMO Asia (Faculty), Singapore, 2019

ILCA Meeting General Sessio II: Clinical TrialsChair, ILCA Annual Meeting 2019, Chicago (USA), 2019

Systemic therapy and new sequences in HCC, What’s next in advanced HCC (Faculty), LondonIndustry Sponsored Event, 2019

Keynote Lecture: Targeting immune regulation within tumours, Imperial College LondonShort Course on Immunology (Faculty), Hammersmith Hospital, 2018

Delivering Precision Oncology in Intermediate-stage hepatocellular cancer, EASL International Liver Meeting Faculty Early Morning Workshop, Amsterdam (NL), 2017

Liver Cancer: Pathogenesis, Screening and Treatment, European HIV Hepatitis Co-infection Meeting Conference (EHHC), British HIV Association, 2015

Personalised cancer care: where were we, where are we, where are we going?, Western Norway Health Care Trust, Helse Vest, Faculty, Stavanger (Norway), 2015

Hepatitis, HIV and malignancy, International Workshop on Co-infection HIV and Hepatitis, London, 2015

Systemic inflammation as a prognostic domain in liver cancer, International Conference: Hepatocellular carcinoma from biology to surgery, IRCCS S. De Bellis, Castellana Grotte, Bari (Italy), 2015

Hepatocellular carcinoma and novel molecular targets: a new hope for the future?, Università degli Studi del Piemonte Orientale "A. Avogadro", Novara (Italy), 2011

Introduction to Drug Discovery, University of Oxford - Doctoral Training Centre, Oxford (UK), 2011

Research Student Supervision

Abdulrahman,A, Circulating free DNA in the diagnosis and molecular phenotyping of hepatocellular carcinoma

Black,J, PRRT in Metastatic Parangagliomas

Brown,M, The role of Axl in acquired sorafenib resistance in hepatocellular carcinoma

Choo,Y, Treatment-stage migration in the use of sorafenib for hepatocellular carcinoma

Cortellini,A, Family history of malignancy as a putative predictive factor of response to cancer immunotherapy

D’Alessio,A, Neoadjuvant immunotherapy of HCC

Dettorre,G, The systemic inflammatory response in patients with COVID-19 and Cancer

Dettorre,G, The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection

Enica,A, Circulating free DNA as a biomarker of benefit to immunotherapy in HCC

Fessas,P, Intra-tumoral heterogeneity influences the tumour microenvironment in primary and secondary HCC.

Gramenitskaya,D, The gut microbiome as a source of predictive biomarkers of response to immunotherapy in HCC.

Hashimoto,T, The natural history of HIV-associated hepatocellular carcinoma

Hussein,N, Antibiotic therapy and outcomes of patients with NSCLC treated with chemo-immunotherapy combinations.

Kalofonou,F, Immunotherapy outcomes in elderly patients undergoing checkpoint inhibitor therapy for cancer.

Kaneko,T, Phenotypic characterisation of HIV-associated hepatocellular carcinoma

Kythreotou,A, The relationship between the sytemic inflammatory response and PD ligands regulation in NSCLC

Mi,E, The inflammatory response in NSCLC patients undergoing immunotherapy

Muhammed,A, The systemic inflammatory response as a predictive marker in HCC patients treated with immunotherapy

Naeem,M, Antibiotic therapy as a prognostic marker in HCC patients treated with immunotherapy

Patel,M, OnCovid: natural history and outcomes of cancer patients during the COVID19 epidemic

Shiraz,J, Systemic Inflammation in the prognosis of HIV-associated hepatocellular carcinoma

Siddique,A, Regulation of Immune-tolerogenic pathways in hepatocellular carcinoma

Su,Y, Regulation of PD ligands in acquired sorafenib resistance in hepatocellular carcinoma

Tsoti,S, The role of Axl in the pathophysiology of neuroendocrine tumours

Victor,S, The relationship between PD ligands expression and activation of the innate immunity in hepatocellular carcinoma

White,S, Identification and clinical significance of PD-L1 positive circulating tumor cells in neuroendocrine tumors

Wong,CN, Tumour mutational burden (TMB) as a stratifying biomarker in HCC.

Yen,C, Treatment-stage migration in the use of sorafenib for hepatocellular carcinoma